Company: SHPH
Filing Date: 2025-02-27
Form Type: 424B3
Source: 0001493152-25-008478
Chunk: 0

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-27
Form: 424B3
Chunk 0
---
Filed Pursuant to Section 424(b)(3)

Registration No. 333-284286

Prospectus Supplement No. 1

(To Prospectus Dated January 23, 2025)

<div align='center'>SHUTTLE PHARMACEUTICALS HOLDINGS, INC.

Up to 1,464,268 Shares of Common Stock Issuable Upon Conversion of 14.5% Senior Secured Convertible Notes

Up to 329,461 Shares of Common Stock Issuable Upon Exercise of Warrants</div>

This prospectus supplement No. 1 updates, amends and supplements the prospectus dated January 23, 2025 (as supplemented or amended from time to time, the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-284286).

This prospectus supplement is being filed to update, amend and supplement the information in the Prospectus with the information contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (the “Commission”) on February 26, 2025 (the “Annual Report”), and a consent from the auditor, Forvis Mazars, LLP, to include their audit report from the Annual Report (the “Auditors’ Consent”). Accordingly, we have attached the Annual Report and the Auditors’ Consent to this prospectus supplement.

The Prospectus and this prospectus supplement relate to the resale from time to time of (i) up to 1,464,268 shares of common stock underlying $831,579 in convertible notes (the “Convertible Notes”), which represents 200% of the maximum number of shares of common stock issuable upon conversion of the Convertible Notes, and (ii) 329,461 shares of common stock issuable upon exercise of warrants (the “Warrants”), each of which were issued in an October 2024 private placement to the selling stockholders named in the Prospectus (the aggregate 1,793,729 shares of common stock being registered that underly the Convertible Notes and Warrants, together, the “Shares”). In compliance with Nasdaq Rule 5635(e), the Company will not issue more than 19.99% of the Company’s common stock issuable under the Convertible Notes, calculated as of October 21, 2024, without first obtaining stockholder approval.

You should read this prospectus supplement